$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

$avdl Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000101247723000018 Filed on August 09, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q4
Revenue	$7.014M	$1.496M	$0.00
YoY Change
Cost Of Revenue	$117.0K	$36.00K
YoY Change
Gross Profit	$6.897M	$1.460M
YoY Change
Gross Profit Margin	98.33%	97.59%
Selling, General & Admin	$39.16M	$46.78M	$16.98M
YoY Change	177.8%	114.54%	-19.24%
% of Gross Profit	567.75%	3203.97%
Research & Development	$2.849M	$4.223M	$6.235M
YoY Change	-2.86%	-7.0%	195.5%
% of Gross Profit	41.31%	289.25%
Depreciation & Amortization	$590.0K	$601.0K	$586.0K
YoY Change	47.13%	143.32%	191.54%
% of Gross Profit	8.55%	41.16%
Operating Expenses	$42.01M	$51.00M	$23.22M
YoY Change	146.68%	93.59%	0.35%
Operating Profit	-$35.11M	-$49.54M
YoY Change	107.02%	65.48%
Interest Expense	-$1.980M	-$2.295M	-$3.255M
YoY Change	-44.44%	-34.54%	-21.64%
% of Operating Profit
Other Income/Expense, Net	$900.0K	$623.0K	-$1.072M
YoY Change	100.89%	224.48%	-265.94%
Pretax Income	-$36.19M	-$64.34M	-$27.37M
YoY Change	80.24%	93.5%	2.71%
Income Tax	$89.00K	$90.00K	$85.00K
% Of Pretax Income
Net Earnings	-$36.27M	-$64.43M	-$27.45M
YoY Change	80.06%	1.56%	23.09%
Net Earnings / Revenue	-517.17%	-4306.95%
Basic Earnings Per Share	-$0.41	-$0.83
Diluted Earnings Per Share	-$0.41	-$0.83	-$0.44
COMMON SHARES
Basic Shares Outstanding	89.37M shares	76.77M shares	61.78M shares
Diluted Shares Outstanding	89.38M shares	77.25M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$153.2M	$160.5M	$96.50M
YoY Change	43.88%	54.16%	-38.62%
Cash & Equivalents	$51.81M	$49.99M	$73.98M
Short-Term Investments	$101.4M	$110.5M	$22.52M
Other Short-Term Assets	$779.0K	$6.463M	$228.0K
YoY Change	37.39%	3083.74%	-15.87%
Inventory	$5.286M	$1.439M	$0.00
Prepaid Expenses	$5.504M	$5.716M	$1.523M
Receivables	$6.239M	$1.775M	$276.0K
Other Receivables	$1.300M	$1.043M	$2.317M
Total Short-Term Assets	$172.3M	$171.2M	$100.8M
YoY Change	52.14%	36.21%	-47.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$648.0K	$1.950M	$839.0K
YoY Change	-27.68%	673.81%	194.39%
Goodwill	$16.84M	$16.84M	$16.84M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.15M	$10.54M	$11.32M
YoY Change	-13.41%	-10.45%	-66.48%
Total Long-Term Assets	$30.85M	$29.75M	$31.94M
YoY Change	-5.2%	-7.69%	-41.69%
TOTAL ASSETS
Total Short-Term Assets	$172.3M	$171.2M	$100.8M
Total Long-Term Assets	$30.85M	$29.75M	$31.94M
Total Assets	$203.1M	$201.0M	$132.8M
YoY Change	39.34%	27.25%	-46.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.26M	$11.79M	$7.890M
YoY Change	435.01%	61.05%	2.75%
Accrued Expenses	$17.96M	$18.59M	$7.334M
YoY Change	125.45%	92.14%	2.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$21.19M	$20.85M	$37.67M
YoY Change	-19.44%	-20.54%
Total Short-Term Liabilities	$54.05M	$51.50M	$55.79M
YoY Change	30.22%	11.44%	165.68%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$91.61M
YoY Change	-100.0%	-100.0%	-35.66%
Other Long-Term Liabilities	$5.818M	$6.282M	$5.743M
YoY Change	1.59%	9.9%	46.62%
Total Long-Term Liabilities	$5.818M	$6.282M	$97.36M
YoY Change	-94.97%	-94.48%	-33.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$54.05M	$51.50M	$55.79M
Total Long-Term Liabilities	$5.818M	$6.282M	$97.36M
Total Liabilities	$92.95M	$57.78M	$153.9M
YoY Change	-41.24%	-64.17%	-8.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$716.7M	-$680.4M	-$585.2M
YoY Change	28.5%	26.56%	30.7%
Common Stock	$852.8M	$849.5M	$590.4M
YoY Change	48.76%	51.53%	7.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$110.1M	$143.2M	-$21.15M
YoY Change
Total Liabilities & Shareholders Equity	$203.1M	$201.0M	$132.8M
YoY Change	39.34%	27.25%	-46.3%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q4
OPERATING ACTIVITIES
Net Income	-$36.27M	-$64.43M	-$27.45M
YoY Change	80.06%	1.56%	23.09%
Depreciation, Depletion And Amortization	$590.0K	$601.0K	$586.0K
YoY Change	47.13%	143.32%	191.54%
Cash From Operating Activities	-$38.22M	-$32.02M	-$15.37M
YoY Change	461.81%	127.27%	-31.72%
INVESTING ACTIVITIES
Capital Expenditures	$0.00		$0.00
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$9.820M	-$92.91M	$22.88M
YoY Change	203.09%	-871.15%	49.31%
Cash From Investing Activities	$9.820M	-$92.91M	$22.87M
YoY Change	289.06%	-871.15%	49.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	30.46M	91.54M	6.622M
YoY Change	184.27%	-2005.98%
NET CHANGE
Cash From Operating Activities	-38.22M	-32.02M	-15.37M
Cash From Investing Activities	9.820M	-92.91M	22.87M
Cash From Financing Activities	30.46M	91.54M	6.622M
Net Change In Cash	2.060M	-33.39M	14.13M
YoY Change	-67.99%	387.76%	-296.65%
FREE CASH FLOW
Cash From Operating Activities	-$38.22M	-$32.02M	-$15.37M
Capital Expenditures	$0.00		$0.00
Free Cash Flow	-$38.22M		-$15.37M
YoY Change	527.9%		-31.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	77246000	shares
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-64432000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	8000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	75000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	83000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-64349000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49985000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	110525000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1775000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1439000	usd
CY2023Q2	avdl	Research And Development Tax Credit Receivable Current ResearchAndDevelopmentTaxCreditReceivableCurrent	974000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6532000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	171230000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	715000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1235000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	16836000	usd
CY2023Q2	avdl	Research And Development Tax Credit Receivable Non Current ResearchAndDevelopmentTaxCreditReceivableNonCurrent	420000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10540000	usd
CY2023Q2	us-gaap	Assets Assets	200976000	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	20851000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	783000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	11786000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17582000	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	500000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	51502000	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	91614000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	490000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5792000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5743000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	57784000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	153930000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5194000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	5194000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	488000	shares
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	52000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	5000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	89321000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	89321000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62878000	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	893000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	628000	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	848626000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	589783000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-680436000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-585220000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-25943000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-26341000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-21145000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	200976000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	132785000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-21145000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30784000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	315000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11913000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	16000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	83000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	134151000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	102162000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1750000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7644000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	143192000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	78244000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-26424000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1102000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1906000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	103000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2505000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0	usd
CY2022Q2	avdl	Adjustments To Additional Paid In Capital Adjustments In Fair Value Of Convertible Debt Conversion Feature AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature	5508000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	658000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3332000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89868000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	506000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2229000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	25870000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9166000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3163000	usd
	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	-13129000	usd
	us-gaap	Deconsolidation Revaluation Of Retained Investment Gain Or Loss Amount DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount	0	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	42000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1206000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1775000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1439000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4400000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-13305000	usd
	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	-2127000	usd
	avdl	Increase Decrease In Research And Development Tax Credit Receivable IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable	-30000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4457000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-62256000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	25618000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	56501000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	113460000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2202000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-87842000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	54299000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	17500000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4357000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	4803000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1779000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2009000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	125986000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2794000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23996000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3420000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50708000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49985000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54128000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4520000	usd
	us-gaap	Interest Paid Net InterestPaidNet	6455000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-14096000	usd
CY2023Q2	avdl	Orphan Drug Exclusivity Term OrphanDrugExclusivityTerm	P7Y
CY2023Q1	avdl	Royalty Financing Quarterly Net Revenue Target RoyaltyFinancingQuarterlyNetRevenueTarget	25000000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	134151000	usd
CY2023Q2	avdl	American Depository Shares Conversion Ratio AmericanDepositorySharesConversionRatio	116.1846	rate
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	12347	shares
CY2023Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1470000	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Reclassifications<span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications are made to prior year amounts whenever necessary to conform with the current year presentation. Certain reclassifications have been made to balances within </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8: Other Assets and Liabilities</span> for the year ended December 31, 2022 to condense line items of the same nature into a single line.
CY2023Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	587000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	112198000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	432000	usd
CY2023Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2105000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	24407000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1889000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	22518000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	usd
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	308000	usd
	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	1031000	usd
CY2023Q2	us-gaap	Inventory Raw Materials And Supplies Net Of Reserves InventoryRawMaterialsAndSuppliesNetOfReserves	50000	usd
CY2023Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	799000	usd
CY2023Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	590000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1439000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	0	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	336000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1019000	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	20851000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	37668000	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	91614000	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	2295000	usd
CY2022Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	3506000	usd
CY2023Q2	avdl	Coupon Interest Expense CouponInterestExpense	1708000	usd
CY2022Q2	avdl	Coupon Interest Expense CouponInterestExpense	1589000	usd
CY2023Q2	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	10098000	usd
CY2022Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1917000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	5554000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	5523000	usd
	avdl	Coupon Interest Expense CouponInterestExpense	3094000	usd
	avdl	Coupon Interest Expense CouponInterestExpense	3206000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2460000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2229000	usd
CY2022Q2	avdl	Debt Instrument Convertible Embedded Conversion Feature Increase Decrease DebtInstrumentConvertibleEmbeddedConversionFeatureIncreaseDecrease	5508000	usd
CY2022Q2	avdl	Adjustments To Additional Paid In Capital Adjustments In Fair Value Of Convertible Debt Conversion Feature AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature	5508000	usd
CY2022Q2	avdl	Debt Instrument Convertible Embedded Conversion Feature Increase Decrease DebtInstrumentConvertibleEmbeddedConversionFeatureIncreaseDecrease	5508000	usd
CY2018Q1	avdl	American Depository Shares Conversion Ratio AmericanDepositorySharesConversionRatio	92.6956	rate
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-13129000	usd
CY2023Q2	avdl	American Depository Shares Conversion Ratio AmericanDepositorySharesConversionRatio	116.1846	rate
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	12347	shares
CY2023Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1470000	usd
CY2023Q1	avdl	Royalty Financing Quarterly Net Revenue Target RoyaltyFinancingQuarterlyNetRevenueTarget	25000000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	90000	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30193000	usd
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.908
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-490000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.005
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25870000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.404
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5716000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1523000	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	747000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	504000	usd
CY2023Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	69000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	69000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6532000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2096000	usd
CY2022Q4	avdl	Operating Lease Right Of Use Asset Contract Manufacturing Noncurrent OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent	10686000	usd
CY2023Q2	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	442000	usd
CY2022Q4	avdl	Other Noncurrent Receivables OtherNoncurrentReceivables	636000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10540000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11322000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	12662000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4040000	usd
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	4405000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1613000	usd
CY2023Q2	avdl	Accrued Trade Discounts And Rebates AccruedTradeDiscountsAndRebates	280000	usd
CY2022Q4	avdl	Accrued Trade Discounts And Rebates AccruedTradeDiscountsAndRebates	0	usd
CY2023Q2	avdl	Accrued Outsource Contract Costs AccruedOutsourceContractCosts	182000	usd
CY2022Q4	avdl	Accrued Outsource Contract Costs AccruedOutsourceContractCosts	1208000	usd
CY2023Q2	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	53000	usd
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	473000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17582000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7334000	usd
CY2023Q2	avdl	Other Liabilities Miscellaneous Current OtherLiabilitiesMiscellaneousCurrent	275000	usd
CY2022Q4	avdl	Other Liabilities Miscellaneous Current OtherLiabilitiesMiscellaneousCurrent	292000	usd
CY2023Q2	avdl	Accrued Interest Current AccruedInterestCurrent	225000	usd
CY2022Q4	avdl	Accrued Interest Current AccruedInterestCurrent	1649000	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	500000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1941000	usd
CY2023Q2	avdl	Tax Liabilities And Other Noncurrent Liabilities TaxLiabilitiesAndOtherNoncurrentLiabilities	5420000	usd
CY2022Q4	avdl	Tax Liabilities And Other Noncurrent Liabilities TaxLiabilitiesAndOtherNoncurrentLiabilities	5246000	usd
CY2023Q2	us-gaap	Guaranty Liabilities GuarantyLiabilities	372000	usd
CY2022Q4	us-gaap	Guaranty Liabilities GuarantyLiabilities	497000	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5792000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5743000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-64432000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-63444000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-95216000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-89868000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	77246000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59037000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	70603000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58931000	shares
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2022Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	77246000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59037000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	70603000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58931000	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.35
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.52
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.35
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.52
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2212000	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22455000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6813000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19042000	shares
CY2023Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	330000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	usd
	avdl	Percentage Of Royalty Payable On Net Sales PercentageOfRoyaltyPayableOnNetSales	0.15
CY2023Q2	us-gaap	Guarantee Obligations Current Carrying Value GuaranteeObligationsCurrentCarryingValue	639000	usd
CY2023Q2	avdl	Guarantee Asset Current Carrying Value GuaranteeAssetCurrentCarryingValue	633000	usd
CY2023Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001012477-23-000018-index-headers.html	Edgar Link	pending
0001012477-23-000018-index.html	Edgar Link	pending
0001012477-23-000018.txt	Edgar Link	pending
0001012477-23-000018-xbrl.zip	Edgar Link	pending
avdl-20230630.htm	Edgar Link	pending
avdl-20230630.xsd	Edgar Link	pending
exhibit101-fourthamendment.htm	Edgar Link	pending
exhibit311q22023.htm	Edgar Link	pending
exhibit312q22023.htm	Edgar Link	pending
exhibit321q22023.htm	Edgar Link	pending
exhibit322q22023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
avdl-20230630_cal.xml	Edgar Link	unprocessable
avdl-20230630_def.xml	Edgar Link	unprocessable
avdl-20230630_lab.xml	Edgar Link	unprocessable
avdl-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
avdl-20230630_htm.xml	Edgar Link	completed
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl

2023 Q3 Form 10-Q Financial Statement

#000101247723000018 Filed on August 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL AVADEL PHARMACEUTICALS PLC Stock $avdl

2023 Q3 Form 10-Q Financial Statement

#000101247723000018 Filed on August 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVDL
AVADEL PHARMACEUTICALS PLC Stock $avdl